Singular: Building Brilliant Biotechs’ Post

When do you need a recruitment process for your venture? What does a good process need to include? How should it sit within your broader business strategy? In the early stages, having a hiring process may seem like something you only need to consider after you've secured your next round of funding. But if you don't factor it into your business strategy early on, you may end up in over your head when you need to scale quickly. Next week we are thrilled to have Tariq Ahmed (Executive Vice President, People Achilles Therapeutics plc) join our nextGEN #founders to share how and why early-stage founders should be thinking about setting up a recruitment process - sharing best practices, tools, and tips from his wealth of experience in HR. Are you a pre-Series A #entrepreneur in #biotech, #medtech, or #digitalhealth? Apply to join us: https://lnkd.in/eYeqd9UR

Life Sciences Industry Sees M&A Surge to continue into 2024 The life sciences industry roared back in 2023 with a near-doubling of M&A investment, reaching a whopping $191 billion! While deal volume dipped slightly, the average deal size skyrocketed by 77%, driven by big pharma dominating the scene. Key takeaways: - Topline pressures due to expiring patents are pushing companies to seek new revenue streams through strategic acquisitions. - Big pharma dominated the scene, accounting for 69% of M&A investment. What's next? - Experts predict continued M&A activity in 2024, with companies focusing on finding the right partners and innovations to secure long-term value. Are you in the life sciences industry? This is the time to sharpen your skills ahead of strategic growth for 2024. #lifesciences #mergersandacquisitions #pharma #healthcare #investment #innovation P.S. Want to discuss the implications of this trend? Let me know.

Breaking into the market with your first drug? Our latest blog dives into the journey from R&D to launch day. Discover how to set your vision, build a patient-centric culture, and attract top talent. Plus, learn how Compass’s expert consultants can keep your launch on schedule. Ready to turn groundbreaking research into real-world impact? Read the blog here: https://lnkd.in/es3HTW8Y #FirstTimeLauncher #DrugLaunchSuccess #DrugLaunchTips #LifeSciencesTrends

🚀 Unlock New Business Opportunities with Our Business Twinning Service! 🚀 At Phenesis we connect businesses across industries to leverage each other’s strengths and unlock growth through Business Twinning. Whether you’re looking to expand into new markets, tap into unique supply chains, or access innovative services, we bring the right partners together to create value. Our Business Twinning Service offers: • Access to sourcing expertise and manufacturing networks across Southeast Asia and China. • Seamless integration of supply chain capabilities with trusted partners. • Tailored solutions that maximize efficiency and reduce costs. By leveraging the capabilities of leading players, we ensure you have access to world-class expertise in quality control, R&D, sourcing, and logistics. 🌍 Whether you’re a startup or a global enterprise, our business twinning approach opens doors to scalable solutions and trusted networks that can help drive your growth. 🔗 Ready to explore new opportunities? Get in touch with us at reachout@phenesis.com to see how we can help you achieve more! #BusinessTwinning #GlobalExpansion #SupplyChain #SourcingSolutions #PartnershipOpportunities

Calling all Pre-seed and Seed stage Biotech companies in the UK and Boston 🚨 We understand that you want to build an amazing company whilst going about your mission to change the medical landscape - but with delivering science and raising money taking priority and finances being allocated elsewhere, it can be difficult to prioritise Culture and People as part of your business' overall strategy. We want to help 💡 so we're offering a free 6 month advisory programme for a limited time only, during which our highly-skilled People Partners will work with you to: 👉🏼 Define the Culture you're intending to create 👉🏼 Drive that Culture, along with engagement, retention and development initiatives for your people 👉🏼 Create a compelling Mission, Purpose and Vision for the long term 👉🏼 Review your hiring processes, job descriptions and proposition to help you attract and secure amazing people 👉🏼 Put in place the systems and processes that will drive your business and save you time and money We'll provide expert advice, introductions, templates, ideas and a whole lot more during a timeframe of 1-2 hours each month over a 6 month period. For more information or to take advantage of this free support, email tom@singular-biotech.com or contact us via our website https://lnkd.in/ebpV4rUE #biotech #techbio #lifesciences #biotechnology #startup #drugdiscovery #drugdevelopment #culture #people

In the biotech and pharma industries, uncertainty is inevitable—particularly when it comes to securing funding. But instead of viewing this as a hurdle, it can actually be an opportunity for strategic growth. A data-driven approach can help life science companies navigate complexity while building confidence with investors. In today’s landscape, investors expect more than a great idea. They want a comprehensive understanding of risks, opportunities, and market dynamics before making any commitments. Here’s a strategy to turn uncertainty into a growth opportunity—click here to see how.

The deep freeze in biotech is beginning to thaw. About half a dozen biotechnology companies have gone public since the start of 2024, with some raising hundreds of millions of dollars. The jump-start to the new year is a welcome sign for the industry after a challenging two years fueled by layoffs, scientific hurdles and rising interest rates, investors say. Fewer than 20 companies went public in both 2022 and 2023. Biotechs have attracted more than $6 billion in follow-on financing since the start of the year through mid-February, which Jefferies analysts say is a record-setting pace—one that has already exceeded each quarterly amount recorded since the second quarter of 2021.  Venture capitalists have invested $3.2 billion in biotechs this year through the middle of February, compared with about $3 billion during the same period in 2023, according to data from research firm PitchBook.  “The healthy market is back,” said Jordan Saxe, head of healthcare listings at Nasdaq, “and it’s not just a fad.” #biotech #investment https://lnkd.in/gf9cgc-A

Early stage biotechs are once again announcing plans to IPO and test the public markets and while exits provide critical capital for fresh investments, are they good for overall health for these nascent organizations? For companies that are preclinical or very early phase, will they have the endurance (and most of all the data) to get to future inflection points that can sustain public interest. Will they have enough early catalysts to sustain them? Thoughts?

📈 We've just released our latest report on navigating Biotech Talent Challenges in 2024. This is a must-read for anyone in the industry who is looking to expand their teams. If you're interested in receiving a copy, send me a quick DM or like this post. Stay ahead of the competition and gain valuable insights to enable growth. #Biotech #TalentChallenges #IndustryInsights #HiringReport

The ice is finally melting in the biotech world! According to The Wall Street Journal, around half a dozen biotech firms have taken the plunge into the public market since the beginning of 2024, raising hundreds of millions of dollars. 📈 This surge in activity marks a promising start to the year for an industry that weathered tough times recently, grappling with layoffs, scientific challenges, and rising interest rates. With fewer than 20 biotech IPOs in both 2022 and 2023, this uptick in public offerings hints at a potential turnaround for the sector. 🔄 Read more about this trend in biotech. Link below! #Biotech #Innovation #MarketTrends #WSJ